Replies to post #213853 on Biotech Values

[lgonber]

The article was written before the FDA decision to accept the NDA and granted priority review, now $ 3.30 as has main risks have vanished. If FDA approves the drug, it will trade at least at $8. grifols is major owner and will be responsible for marketing.